| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c38c1cb24317837bc585819824b386d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a05eadea97eec51a457572c73ce586f4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-5304
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 |
| filingDate |
1977-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97df50cad32b47cd724411d78599710e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f1d1eb237a7a9ba3b6d088d2a972b6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c3b239da08ed698785025d7ac3e25e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c24bffa34e9dcf213a513e0249dde4a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93eb579b2ee4dc0bd4a9f7417d6b22fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ac8196f08f3b6f6765e729ebc1fcedf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8f11ad43ade71917e643d0a0e02d26a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cc517199fae1f7a3bb34df853d786fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e1efd3f067e88fc188597fda2071561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15e8a0ed1fe919cbaa204576c8a7c1cf |
| publicationDate |
1979-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
DE-2751389-A1 |
| titleOfInvention |
MEDICINAL PRODUCTS WITH EXPRESSED VEGETOTROPIC AND ANTIEPILEPTIC EFFECTS FOR THE TREATMENT OF MENTAL AND NERVOUS DISEASES |
| abstract |
A pharmaceutical with excellent vehetotropic and antieliptic activities and which can be used in the treatment of psychic and nervous disorders, contains diphenyl phosphinyl acetic acid hydrazide of formula: Ph2P(=O)CH2-C(=O)NHH2 (I) and a filler. (I) are relatively weak tranquilisers, and the main effect is on the centres of vegetative regulation in the hypothalamic and edge structures of the brain, in which the epileptogenic centre in temporal epilepsy is situated. (I) also protects against the group toxicity of phenamine (aphetamine). (I) causes no local irritation and is of low toxicity (LD5o for mice is 293 mg/kg i.v.). Suitable daily doses are 1.0-3.0 g (taken in units of 0.5-1.0g, 2 to 3 times daily). The treatment takes 1 week to 1 1/2 to 2 months and in temporal epilepsy up to 3-5 months. |
| priorityDate |
1977-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |